Development of gene therapy: Potential in severe combined immunodeficiency due to adenosine deaminase deficiency

Stem Cells and Cloning: Advances and Applications

Volumn 3, Issue 1, 2010, Pages 1-12

  Montiel Equihua, Claudia A ^a   Thrasher, Adrian J ^a   Gaspar, H Bobby ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Adenosine deaminase; Clinical trial; Gene therapy; Hematopoietic stem cell; Retrovirus; Severe combined immunodeficiency

Indexed keywords

ADENOSINE DEAMINASE; COMPLEMENTARY DNA; PEGADEMASE; RETROVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG MEGADOSE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME REPLACEMENT; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LOW DRUG DOSE; LUNG INSUFFICIENCY; NONHUMAN; PATHOGENESIS; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; STEM CELL GENE THERAPY; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM;

EID: 77958583417     PISSN: None     EISSN: 11786957     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Fischer A, Le DF, Hacein-Bey-Abina S, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev. 2005;203:98-109.
2. Hershfield MS, Mitchell BS. Immunodeficiency diseases caused by adenosine deaminase deficiency and purine nucleoside phosphorylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill; 1995. p. 1725-1768.
3. Lee N, Russell N, Ganeshaguru K, et al. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase. Br J Haematol. 1984;56(1):107-119.
4. Apasov SG, Blackburn MR, Kellems RE, Smith PT, Sitkovsky MV. Adenosine deaminase deficiency increases thymic apoptosis and causes defective T cell receptor signaling. J Clin Invest. 2001;108(1): 131-141.
5. Gangi-Peterson L, Sorscher DH, Reynolds JW, Kepler TB, Mitchell BS. Nucleotide pool imbalance and adenosine deaminase deficiency induce alterations of N-region insertions during V(D)J recombination. J Clin Invest. 1999;103(6):833-841.
6. Benveniste P, Zhu W, Cohen A. Interference with thymocyte differentiation by an inhibitor of S-adenosylhomocysteine hydrolase. J Immunol. 1995;155(2):536-544.
7. Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur J Immunol. 2005;35(1):25-30.
8. Cassani B, Mirolo M, Cattaneo F, et al. Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. Blood. 2008;111(8):4209-4219.
9. Blackburn MR, Kellems RE. Adenosine deaminase deficiency: metabolic basis of immune deficiency and pulmonary inflammation. Adv Immunol. 2005;86:1-41.
10. Booth C, Hershfield M, Notarangelo L, et al. Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol. 2007; 123(2):139-147.
11. Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rosen FS. Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J Clin Invest. 1981;68(6):1387-1393.
12. Booth C, Gaspar HB. Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID). Biologics: 2009;3:349-358.
13. Mortellaro A, Hernandez RJ, Guerrini MM, et al. Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. Blood. 2006; 108(9):2979-2988.
14. Rogers MH, Lwin R, Fairbanks L, Gerritsen B, Gaspar HB. Cognitive and behavioral abnormalities in adenosine deaminase deficient severe combined immunodeficiency. J Pediatr. 2001;139(1):44-50.
15. Honig M, Albert MH, Schulz A, et al. Patients with adenosine deaminase deficiency surviving after hematopoietic stem cell transplantation are at high risk of CNS complications. Blood. 2007;109(8):3595-3602.
16. Titman P, Pink E, Skucek E, et al. Cognitive and behavioral abnormalities in children after hematopoietic stem cell transplantation for severe congenital immunodeficiencies. Blood. 2008;112(9):3907-3913.
17. Gaspar HB, Aiuti A, Porta F, Candotti F, Hershfield MS, Notarangelo LD. How I treat ADA deficiency. Blood. 2009;114(17):3524-3532.
18. Chan B, Wara D, Bastian J, et al. Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin Immunol. 2005;117(2):133-143.
19. Malacarne F, Benicchi T, Notarangelo LD, et al. Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. Eur J Immunol. 2005;35(11):3376- 3386.
20. Bollinger ME, Arredondo-Vega FX, Santisteban I, Schwarz K, Hershfield MS, Lederman HM. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. N Engl J Med. 1996;334(21):1367-1371.
21. Blackburn MR, Aldrich M, Volmer JB, et al. The use of enzyme therapy to regulate the metabolic and phenotypic consequences of adenosine deaminase deficiency in mice. Differential impact on pulmonary and immunologic abnormalities. J Biol Chem. 2000;275(41): 32114-32121.
22. Hirschhorn R. Immunodeficiency due to adenosine deaminase. In: Ochs HD, Smith CIE, Puck JM, editors. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, NY: Oxford University Press Inc, USA; 1998.
23. Daddona PE, Mitchell BS, Meuwissen HJ, Davidson BL, Wilson JM, Koller CA. Adenosine deaminase deficiency with normal immune function. An acidic enzyme mutation. J Clin Invest. 1983;72(2):483-492.
24. Hirschhorn R. In vivo reversion to normal of inherited mutations in humans. J Med Genet. 2003;40(10):721-728.
25. Wiginton DA, Adrian GS, Friedman RL, Suttle DP, Hutton JJ. Cloning of cDNA sequences of human adenosine deaminase. Proc Natl Acad Sci U S A. 1983;80(24):7481-7485.
26. Valerio D, McIvor RS, Williams SR, et al. Cloning of human adenosine deaminase cDNA and expression in mouse cells. Gene. 1984;31(1-3): 147-153.
27. Daddona PE, Shewach DS, Kelley WN, Argos P, Markham AF, Orkin SH. Human adenosine deaminase. cDNA and complete primary amino acid sequence. J Biol Chem. 1984;259(19):12101-12106.
28. Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;2(7786):1067-1069.
29. Valerio D, Duyvesteyn MG, van der Eb AJ. Introduction of sequences encoding functional human adenosine deaminase into mouse cells using a retroviral shuttle system. Gene. 1985;34(2-3):163-168.
30. Friedman RL. Expression of human adenosine deaminase using a transmissable murine retrovirus vector system. Proc Natl Acad Sci U S A. 1985;82(3):703-707.
31. Kantoff PW, Kohn DB, Mitsuya H, et al. Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A. 1986;83(17):6563-6567.
32. Joyner A, Keller G, Phillips RA, Bernstein A. Retrovirus transfer of a bacterial gene into mouse haematopoietic progenitor cells. Nature. 1983;305(5934):556-558.
33. Keller G, Paige C, Gilboa E, Wagner EF. Expression of a foreign gene in myeloid and lymphoid cells derived from multipotent haematopoietic precursors. Nature. 1985;318(6042):149-154.
34. Eglitis MA, Kantoff P, Gilboa E, Anderson WF. Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science. 1985;230(4732):1395-1398.
35. Belmont JW, Henkel-Tigges J, Chang SM, et al. Expression of human adenosine deaminase in murine haematopoietic progenitor cells following retroviral transfer. Nature.1986;322(6077):385-387.
36. Lim B, Apperley JF, Orkin SH, Williams DA. Long-term expression of human adenosine deaminase in mice transplanted with retrovirus-infected hematopoietic stem cells. Proc Natl Acad Sci U S A. 1989; 86(22):8892-8896.
37. Wilson JM, Danos O, Grossman M, Raulet DH, Mulligan RC. Expression of human adenosine deaminase in mice reconstituted with retrovirus-transduced hematopoietic stem cells. Proc Natl Acad Sci U S A. 1990;87(1):439-443.
38. Kantoff PW, Gillio AP, McLachlin JR, et al. Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer. J Exp Med. 1987;166(1):219-234.
39. Bodine DM, McDonagh KT, Brandt SJ, et al. Development of a high-titer retrovirus producer cell line capable of gene transfer into rhesus monkey hematopoietic stem cells. Proc Natl Acad Sci U S A. 1990;87(10):3738-3742.
40. van BV, Kukler A, Heidt PJ, Valerio D. Long-term expression of human adenosine deaminase in rhesus monkeys transplanted with retrovirus-infected bone-marrow cells. Proc Natl Acad Sci U S A. 1992;89(16):7640-7644.
41. Nolta JA, Kohn DB. Comparison of the effects of growth factors on retroviral vector-mediated gene transfer and the proliferative status of human hematopoietic progenitor cells. Hum Gene Ther. 1990;1(3):257-268.
42. Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T-cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med. 1992;176(4):1125-1135.
43. Vanin EF, Kaloss M, Broscius C, Nienhuis AW. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis. J Virol.1994;68(7):4241-4250.
44. Ferrari G, Rossini S, Giavazzi R, et al. An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science. 1991;251(4999):1363-1366.
45. Culver KW, Morgan RA, Osborne WR, et al. In vivo expression and survival of gene-modified T lymphocytes in rhesus monkeys. Hum Gene Ther. 1990;1(4):399-410.
46. Blaese RM, Culver KW, Miller AD, et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science. 1995;270(5235):475-480.
47. Onodera M, Ariga T, Kawamura N, et al. Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood. 1998;91(1):30-36.
48. Bordignon C, Notarangelo LD, Nobili N, et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients. Science. 1995;270(5235):470-475.
49. Kohn DB, Weinberg KI, Nolta JA, et al. Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat Med. 1995;1(10):1017-1023.
50. Hoogerbrugge PM, van BV, Fischer A, et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 1996;3(2):179-183.
51. Aiuti A, Vai S, Mortellaro A, et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med. 2002;8(5):423-425.
52. Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B. Isolation of a candidate human hematopoietic stem-cell population. Proc Natl Acad Sci U S A. 1992;89(7):2804-2808.
53. Luens KM, Travis MA, Chen BP, Hill BL, Scollay R, Murray LJ. Thrombopoietin, kit ligand, and flk2/flt3 ligand together induce increased numbers of primitive hematopoietic progenitors from human CD34+Thy-1+Lin- cells with preserved ability to engraft SCID-hu bone. Blood. 1998;91(4):1206-1215.
54. Cavazzana-Calvo M, Hacein-Bey S, de Saint BG, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672.
55. Hanenberg H, Hashino K, Konishi H, Hock RA, Kato I, Williams DA. Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum Gene Ther. 1997;8(18):2193-2206.
56. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 2002;296(5577):2410-2413.
57. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009;360(5): 447-458.
58. Aiuti A, Cassani B, Andolfi G, et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest. 2007;117(8): 2233-2240.
59. Gaspar HB, Bjorkegren E, Parsley K, et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther. 2006;14(4):505-513.
60. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-3142.
61. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143-3150.
62. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300(5626):1749- 1751.
63. Montini E, Cesana D, Schmidt M, et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J Clin Invest. 2009;119(4):964-975.
64. Charrier S, Dupre L, Scaramuzza S, et al. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther. 2007;14(5):415-428.
65. Modlich U, Bohne J, Schmidt M, et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood. 2006;108(8):2545-2553.
66. Zychlinski D, Schambach A, Modlich U, et al. Physiological Promoters reduce the genotoxic risk of integrating gene vectors. Mol Ther. 2008;16(4):718-725.
67. Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24(6):687-696.
68. Schambach A, Bohne J, Chandra S, et al. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol Ther. 2006;13(2):391-400.
69. Zhang F, Thornhill SI, Howe SJ, et al. Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood. 2007;110(5):1448-1457.
70. Strachan T, Read AP. Human Molecular Genetics 2. 2nd ed.Wilmington, DE: Wiley-Liss; 1999.
71. Gaszner M, Felsenfeld G. Insulators: exploiting transcriptional and epigenetic mechanisms. Nat Rev Genet. 2006;7(9):703-713.
72. Chung JH, Whiteley M, Felsenfeld G. A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell. 1993;74(3): 505-514.
73. Chung JH, Bell AC, Felsenfeld G. Characterization of the chicken beta-globin insulator. Proc Natl Acad Sci U S A. 1997;94(2):575-580.
74. Li CL, Xiong D, Stamatoyannopoulos G, Emery DW. Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol Ther. 2009;17(4):716-724.
75. Ryu BY, Evans-Galea MV, Gray JT, Bodine DM, Persons DA, Nienhuis AW. An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood. 2008;111(4):1866-1875.
76. Urbinati F, Arumugam P, Higashimoto T, et al. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. Mol Ther. 2009;17(9):1527-1536.
77. Ramezani A, Hawley TS, Hawley RG. Stable gammaretroviral vector expression during embryonic stem cell-derived in vitro hematopoietic development. Mol Ther. 2006;14(2):245-254.
78. Ramezani A, Hawley TS, Hawley RG. Combinatorial incorporation of enhancer-blocking components of the chicken beta-globin 5′HS4 and human T-cell receptor alpha/delta BEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells. 2008;26(12):3257-3266.
79. Mitra K, Lenz J. A combinatorial insulator approach confers effective protection against insertional activation of oncogenes in a stringent tumorigenesis model. Mol Ther. 2009:27;17(Suppl 1):S142.
80. Bokhoven M, Stephen SL, Knight S, et al. Insertional gene activation by lentiviral and gammaretroviral vectors. J Virol. 2009;83(1):283-294.